Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies.

Nichols, Russell; Doty, Erin; Sacco, Sara; Ruff, Dustin; Pearlman, Eric; Aurora, Sheena K

Nichols, Russell; Doty, Erin; Sacco, Sara; Ruff, Dustin; Pearlman, Eric; Aurora, Sheena K.

Affiliation

Nichols R; Eli Lilly and Company, and/or one of its subsidiaries, Indianapolis, IN, USA.
Doty E; Eli Lilly and Company, and/or one of its subsidiaries, Indianapolis, IN, USA.
Sacco S; First Coast Neurosciences, Jacksonville, FL, USA.
Ruff D; Carolinas Headache Clinic, Matthews, NC, USA.
Pearlman E; Eli Lilly and Company, and/or one of its subsidiaries, Indianapolis, IN, USA.
Aurora SK; Eli Lilly and Company, and/or one of its subsidiaries, Indianapolis, IN, USA.

Headache ; 59(2): 192-204, 2019 02.

Article in En | MEDLINE | ID: mdl-30462830

Subject(s)

Analgesics/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Migraine Disorders/drug therapy; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Time Factors; Treatment Failure

Key words

chronic; continued treatment; episodic; initial response; migraine; preventive

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Analgesics / Migraine Disorders Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Headache Year: 2019 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google